Advance understanding of AMR and accelerate drug discovery through a unified, multidisciplinary strategy.
Connecting molecular, clinical, epidemiological, and policy perspectives, the ARDD will enhance GHTM’s capacity to generate actionable knowledge and evidence-based solutions for combating resistance in bacteria, parasites, and viruses.
A GHTM Antimicrobial Resistance Network (GHTM-AMRN) will be established to promote data sharing and joint analysis across microbial, vector, and human health domains, supporting genomic epidemiology, GWAS, and AI driven prediction of resistance mechanisms. Collaborative research will focus on developing and testing new antimicrobial candidates and repurposed drugs through a GHTM Drug Discovery Hub, combining CADD, Artificial Intelligence (AI) molecular modeling, and in vivo/in vitro infection systems.
PRIME will lead genomic and molecular studies, CTM will evaluate clinical applications, VBD will contribute with vector-pathogen insights, and PPS will assess implementation feasibility and health policy implications. This integrative framework will strengthen pandemic preparedness, treatment innovation, and evidence-based control strategies for tropical and global infectious diseases.
Capacity building and translation will be key pillars of the ARDD CCI. Annual training programs and postgraduate exchanges will promote interdisciplinary skills in diagnostics, resistance mapping, and pharmacological innovation, while South–South collaborations will expand field validation and clinical research capacity, in collaboration with policymakers to align research outputs with One Health-WHO Global AMR Action Plan goals, promoting sustainable innovation and equitable health impact
Recent Highlights
World Zoonoses Day: GHTM Highlights National One Health Research as the Week Comes to a Close
Explore GHTM’s One Health research on canine leishmaniasis and leptospirosis, advancing zoonotic disease surveillance in Portugal.
Read More
World Zoonoses Day: GHTM research advances One Health solutions for zoonotic diseases
Explore how GHTM research is strengthening One Health through advances in leishmaniasis, leptospirosis and vector-borne diseases.
Read More
